Fox Run Management L.L.C. Makes New Investment in Gilead Sciences, Inc. $GILD

Fox Run Management L.L.C. acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,259 shares of the biopharmaceutical company’s stock, valued at approximately $1,361,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $26,000. Putney Financial Group LLC lifted its stake in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences in the second quarter worth about $30,000. MTM Investment Management LLC grew its stake in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 317,085 shares of company stock worth $44,734,886 in the last quarter. Insiders own 0.27% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New Phase 3 results (ARTISTRY‑1 and ARTISTRY‑2) show Gilead’s investigational single‑tablet bictegravir/lenacapavir regimen maintained virological suppression in people switching therapy — a meaningful data point for switching patients and long‑term market share. Gilead’s Single-Tablet Regimen Maintained Virological Suppression (BusinessWire)
• Positive Sentiment: Independent coverage reports the experimental single‑tablet regimen was generally well tolerated with low discontinuation rates, supporting commercial viability if approved. Gilead’s experimental HIV treatment shows low discontinuation rates in studies (Reuters)
• Positive Sentiment: Gilead agreed to acquire Arcellx for $7.8B to gain full control of anito‑cel, strengthening its cell therapy / oncology pipeline — a strategic bolt‑on that could drive long‑term growth beyond HIV. Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy (Benzinga)
• Positive Sentiment: Analyst activity is supportive: Needham reaffirmed a Buy and at least one outlet reports an 11.7% higher price target — signals that sell‑side expectations are improving. Needham & Company LLC Reaffirms Buy Rating for Gilead Sciences (AmericanBankingNews)
• Positive Sentiment: Market commentary notes a raised price target to about $159, reflecting bullish analyst revisions following the recent data and deal. Gilead Sciences (GILD) price target increased by 11.73% to 159.01 (MSN)
• Neutral Sentiment: Broader market/sector headlines (e.g., macro or AI “halo” trade commentary) are likely distracting investors but are not specific to Gilead’s fundamentals. Hypothetical AI Doomsday Scenario Lights Up Wall Street’s HALO Trade (The Daily Upside)
• Negative Sentiment: Competitive risk: Merck’s two‑drug HIV regimen reportedly matched Gilead’s Biktarvy in Phase 3 and is under FDA review — increased competition in HIV could pressure long‑run pricing and market share. Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. (Yahoo/WSJ)

Gilead Sciences Price Performance

Shares of GILD stock opened at $147.12 on Thursday. The firm has a market cap of $182.53 billion, a P/E ratio of 21.73, a P/E/G ratio of 1.76 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The firm has a fifty day moving average of $135.16 and a two-hundred day moving average of $124.44.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the business posted $1.90 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s payout ratio is currently 46.68%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Truist Financial upped their price target on Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. TD Cowen boosted their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Citigroup raised their price target on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. UBS Group lifted their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Mizuho upped their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Twenty-three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $155.44.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.